Neutralizing antibodies for the prevention and treatment of COVID-19.
Neutralizing antibodies for the prevention and treatment of COVID-19.
复制标题
DOI：
10.1038/s41423-021-00752-2
复制
发表时间：
2021-10
影响因子：
24.1
通讯作者：
Zhang X
中科院分区：
文献类型：
--
作者：
Du L;Yang Y;Zhang X
严重急性呼吸综合征冠状病毒-2 （SARS-CoV-2）通过病毒刺突(S)蛋白S1亚基的受体结合域（RBD）与病毒细胞受体血管紧张素转换酶2结合，从而启动感染过程。这一事件之后是由S2亚基介导的病毒与细胞膜融合，从而允许病毒进入宿主细胞。因此，sars - cov - 2s蛋白是一个关键的治疗靶点，针对该蛋白的中和性单克隆抗体（nab）的开发是预防和治疗新冠肺炎（COVID-19）的重点。本文综述了迄今为止开发的靶向SARS-CoV-2蛋白的nab，重点介绍了S蛋白的n端结构域和RBD。我们还描述了这些nAb提供的结合亲和力、中和活性和保护在预防和治疗COVID-19中的作用，并讨论了提高nAb对抗多种SARS-CoV-2变体效率的潜力。这一综述为开发针对当前和未来SARS-CoV-2株具有广谱活性的有效抗体提供了重要信息。
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through the receptor-binding domain (RBD) in the S1 subunit of the viral spike (S) protein. This event is followed by virus–cell membrane fusion mediated by the S2 subunit, which allows virus entry into the host cell. Therefore, the SARS-CoV-2 S protein is a key therapeutic target, and prevention and treatment of coronavirus disease 2019 (COVID-19) have focused on the development of neutralizing monoclonal antibodies (nAbs) that target this protein. In this review, we summarize the nAbs targeting SARS-CoV-2 proteins that have been developed to date, with a focus on the N-terminal domain and RBD of the S protein. We also describe the roles that binding affinity, neutralizing activity, and protection provided by these nAbs play in the prevention and treatment of COVID-19 and discuss the potential to improve nAb efficiency against multiple SARS-CoV-2 variants. This review provides important information for the development of effective nAbs with broad-spectrum activity against current and future SARS-CoV-2 strains.
登录
查看更多内容
DOI：
10.1056/nejmoa2029849
发表时间：
2021-01-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Chen P;Nirula A;Heller B;Gottlieb RL;Boscia J;Morris J;Huhn G;Cardona J;Mocherla B;Stosor V;Shawa I;Adams AC;Van Naarden J;Custer KL;Shen L;Durante M;Oakley G;Schade AE;Sabo J;Patel DR;Klekotka P;Skovronsky DM;BLAZE-1 Investigators
通讯作者：
BLAZE-1 Investigators
影响因子：
64.5
作者：
Dejnirattisai W;Zhou D;Ginn HM;Duyvesteyn HME;Supasa P;Case JB;Zhao Y;Walter TS;Mentzer AJ;Liu C;Wang B;Paesen GC;Slon-Campos J;López-Camacho C;Kafai NM;Bailey AL;Chen RE;Ying B;Thompson C;Bolton J;Fyfe A;Gupta S;Tan TK;Gilbert-Jaramillo J;James W;Knight M;Carroll MW;Skelly D;Dold C;Peng Y;Levin R;Dong T;Pollard AJ;Knight JC;Klenerman P;Temperton N;Hall DR;Williams MA;Paterson NG;Bertram FKR;Siebert CA;Clare DK;Howe A;Radecke J;Song Y;Townsend AR;Huang KA;Fry EE;Mongkolsapaya J;Diamond MS;Ren J;Stuart DI;Screaton GR
通讯作者：
Screaton GR
影响因子：
5
作者：
Behloul, Nouredine;Baha, Sarra;Meng, Jihong
通讯作者：
Meng, Jihong
REGN-COV2抗体预防和治疗恒河猕猴和仓鼠中的SARS-COV-2感染。
DOI：
10.1126/science.abe2402
发表时间：
2020-11-27
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Baum A;Ajithdoss D;Copin R;Zhou A;Lanza K;Negron N;Ni M;Wei Y;Mohammadi K;Musser B;Atwal GS;Oyejide A;Goez-Gazi Y;Dutton J;Clemmons E;Staples HM;Bartley C;Klaffke B;Alfson K;Gazi M;Gonzalez O;Dick E Jr;Carrion R Jr;Pessaint L;Porto M;Cook A;Brown R;Ali V;Greenhouse J;Taylor T;Andersen H;Lewis MG;Stahl N;Murphy AJ;Yancopoulos GD;Kyratsous CA
通讯作者：
Kyratsous CA
影响因子：
64.5
作者：
Andreano E;Nicastri E;Paciello I;Pileri P;Manganaro N;Piccini G;Manenti A;Pantano E;Kabanova A;Troisi M;Vacca F;Cardamone D;De Santi C;Torres JL;Ozorowski G;Benincasa L;Jang H;Di Genova C;Depau L;Brunetti J;Agrati C;Capobianchi MR;Castilletti C;Emiliozzi A;Fabbiani M;Montagnani F;Bracci L;Sautto G;Ross TM;Montomoli E;Temperton N;Ward AB;Sala C;Ippolito G;Rappuoli R
通讯作者：
Rappuoli R